Pulmonary-Allergy Drugs Advisory Committee
Executive Summary
Committee will meet April 20 to review Astra USA's Pulmicort Respules (budesonide nebulizing suspension, NDA 20-929) for maintenance and treatment of asthma and for the prophylactic treatment of asthma in children six to eight years old and in children six months to eight years old who require systemic corticosteroid administration where adding Pulmicort Respules may reduce or eliminate need for corticosteroids. The meeting will begin at 8 a.m. at the Hilton in Gaithersburg, Md...